NANJING VAZYME BIOTECH CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.49 CNY | -1.30% |
|
-4.63% | -26.64% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 42,401 | 21,257 | 12,808 | 9,326 | - |
| Enterprise Value (EV) 1 | 42,401 | 21,257 | 12,808 | 9,326 | 9,326 |
| P/E ratio | 56.7 x | 35.7 x | -178 x | 19.4 x | 22 x |
| Yield | - | 2.35% | 0.31% | 1.28% | 1.28% |
| Capitalization / Revenue | 22.7 x | 5.96 x | 9.96 x | 5.83 x | 4.64 x |
| EV / Revenue | 22.7 x | 5.96 x | 9.96 x | 5.83 x | 4.64 x |
| EV / EBITDA | 51.1 x | 24.3 x | 169 x | 21.2 x | 14.8 x |
| EV / FCF | - | -100,216,237 x | - | - | - |
| FCF Yield | - | -0% | - | - | - |
| Price to Book | 10.3 x | 4.61 x | 3.18 x | 2.05 x | 1.94 x |
| Nbr of stocks (in thousands) | 400,010 | 400,010 | 400,010 | 396,999 | - |
| Reference price 2 | 106.0 | 53.14 | 32.02 | 23.49 | 23.49 |
| Announcement Date | 25/02/22 | 27/02/23 | 28/02/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | 1,869 | 3,569 | 1,286 | 1,600 | 2,011 |
| EBITDA 1 | 830.3 | 875.7 | 75.74 | 439.4 | 631.2 |
| EBIT 1 | 771.1 | 717.5 | -100.2 | 290.8 | 430.4 |
| Operating Margin | 41.27% | 20.1% | -7.79% | 18.17% | 21.4% |
| Earnings before Tax (EBT) 1 | 764.4 | 609.4 | -115.7 | 246.7 | 394.7 |
| Net income 1 | 678.3 | 594.2 | -70.96 | 485.7 | 467.3 |
| Net margin | 36.3% | 16.65% | -5.52% | 30.35% | 23.24% |
| EPS 2 | 1.870 | 1.490 | -0.1800 | 1.210 | 1.068 |
| Free Cash Flow | - | -212.1 | - | - | - |
| FCF margin | - | -5.94% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | 1.250 | 0.1000 | 0.3000 | 0.3000 |
| Announcement Date | 25/02/22 | 27/02/23 | 28/02/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 |
|---|---|---|---|
| Net sales 1 | - | 268.8 | 298.3 |
| EBITDA | - | - | - |
| EBIT 1 | - | -40 | 9.534 |
| Operating Margin | - | -14.88% | 3.2% |
| Earnings before Tax (EBT) 1 | - | - | -1.293 |
| Net income 1 | -50.62 | - | 4.704 |
| Net margin | - | - | 1.58% |
| EPS 2 | -0.1300 | -0.0700 | 0.0100 |
| Dividend per Share | - | - | - |
| Announcement Date | 26/04/23 | 29/08/23 | 28/10/23 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | -212 | - | - | - |
| ROE (net income / shareholders' equity) | 40.5% | 13.6% | -1.55% | 10.1% | 8.47% |
| ROA (Net income/ Total Assets) | 21.9% | 11.2% | - | 3.8% | 6.5% |
| Assets 1 | 3,103 | 5,306 | - | 12,783 | 7,189 |
| Book Value Per Share 2 | 10.30 | 11.50 | 10.10 | 11.50 | 12.10 |
| Cash Flow per Share 2 | 1.540 | 1.840 | 0.3800 | 0.7100 | 1.340 |
| Capex 1 | 259 | 947 | 219 | 371 | 432 |
| Capex / Sales | 13.87% | 26.54% | 17.06% | 23.21% | 21.48% |
| Announcement Date | 25/02/22 | 27/02/23 | 28/02/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
23.49
CNY
Average target price
35.72
CNY
Spread / Average Target
+52.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.64% | 1.29B | |
| +38.51% | 727B | |
| +33.05% | 599B | |
| -6.23% | 354B | |
| +18.78% | 328B | |
| +1.35% | 277B | |
| +16.00% | 243B | |
| +8.09% | 205B | |
| -5.77% | 203B | |
| +6.19% | 164B |
- Stock Market
- Equities
- 688105 Stock
- Financials Nanjing Vazyme Biotech Co.,Ltd
